Basilea Pharmaceutica Ltd (BPMUF)
44.45
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 533.48M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -14.52% |
| Valuation | |
| PE Ratio | 66.07 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.246 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -11.09 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 74.23% |
Profile
| Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. Its commercial product comprises of Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. |
| URL | https://www.basilea.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. Its commercial product comprises of Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. |
| URL | https://www.basilea.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |